|Bid||172.09 x 300|
|Ask||172.19 x 100|
|Day's Range||171.71 - 173.23|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.33|
|Dividend & Yield||4.60 (2.54%)|
|1y Target Est||N/A|
Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha. The FDA will decide by Dec. 2 whether to allow Amgen to include data from a major clinical trial that showed Repatha significantly cut the risk of heart attack, stroke and death in addition to dramatically lowering bad LDL cholesterol, the company said.
Amgen, Inc. (NASDAQ: AMGN ) Tuesday earnings report was of "poor-quality" and the company doesn't have any near-term catalysts to support the stock, analysts at BMO Capital Markets said. Analyst ...